Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes

Breast Cancer Research

Table 3 Multivariate Cox proportional hazards model for disease-free survival and cancer-specific survival

	Disease-free survival			Cancer-specific survival
	P-value	Hazard ratio	95 % CI	P-value	Hazard ratio	95 % CI
Metformin
Metformin		1			1
Non-metformin versus metformin	0.025	1.59	1.06 to 2.39	0.009	1.85	1.17 to 2.92
Non-DM versus metformin	0.483	0.90	0.66 to 1.22	0.519	0.89	0.62 to 1.27
Age, years
≤50	0.584	1.04	0.92 to 1.17	0.106	0.89	0.77 to 1.03
Body mass index, kg/m2
High		1			1
Low versus high	0.009	1.17	1.1 to 1.17	0.018	1.52	1.08 to 2.14
Normal versus high	0.639	1.03	0.91 to 1.17	0.597	1.04	0.90 to 1.21
Tumor size, cm
T ≥2	<0.001	2.03	1.78 to 2.31	<0.001	2.18	1.86 to 2.56
Node metastasis
Node positive	<0.001	2.59	2.26 to 2.96	<0.001	3.09	2.63 to 3.64
Estrogen receptor status
Positive	0.009	0.79	0.66 to 0.94	0.026	0.78	0.63 to 0.97
Progesterone receptor status
Positive	0.004	0.80	0.68 to 0.93	0.001	0.72	0.60 to 0.87
HER2 status
Positive	<0.001	1.27	1.13 to 1.44	<0.001	1.29	1.12 to 1.49
Chemotherapy
Yes	<0.001	0.70	0.58 to 0.84	0.098	0.82	0.65 to 1.04
Endocrine therapy
Yes	0.312	0.91	0.75 to 1.10	0.108	0.83	0.67 to 1.04

ISSN: 1465-542X